查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1992449

化療設備市場：按產品類型、治療方法、應用和最終用戶分類－2026-2032年全球市場預測

Chemotherapy Device Market by Product Type, Modality, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年化療設備市值為38.4億美元，預計2026年將成長至41.1億美元，複合年成長率為7.51%，到2032年將達到63.8億美元。

主要市場統計數據
基準年 2025 38.4億美元
預計年份：2026年 41.1億美元
預測年份 2032 63.8億美元
複合年成長率 (%) 7.51%

對化療設備市場進行全面概述，重點在於臨床需求、技術進步、監管趨勢和優先事項。

本執行摘要首先簡要概述了化療器械領域，重點闡述了推動其應用的臨床背景、關鍵技術類別以及相關人員的優先事項。隨著臨床醫師和醫療系統不斷追求更安全、更精準、以病人為中心的治療方法，以減少輸液錯誤、縮短住院時間並提高治療的連續性，化療方式也不斷發展。同時，器械創新者正致力於提升互通性、易用性和實證醫學證據，以滿足監管機構、支付方和醫療團隊日益成長的期望。

探索變革性變化，重新定義化療醫療設備創新、臨床工作流程、監管預期和以病人為中心的給藥模式。

在化療設備領域，一系列變革正在發生，其驅動力來自於設備小型化、互聯互通和人體工學的進步。新型設備外形和整合的安全功能正在重新定義臨床工作流程，使患者能夠在家庭和門診環境中接受更貼近的治療。同時，數位化工具和數據收集能力正在幫助臨床醫生進行更嚴格的監管、遠端監測和上市後證據收集，所有這些共同加速了產品的迭代改進和臨床應用。

評估近期美國關稅政策對化療醫療器材供應鏈、採購方式和臨床應用的累積影響。

美國近期推出的關稅措施正對化療醫療設備的整個生態系統，包括生產、採購和購買管道，造成累積壓力。擁有全球供應鏈的製造商面臨原料成本飆升和供應重新分配的困境，而採購團隊和醫院採購部門則需要重新評估籌資策略，以維持預算的可預測性。此外，關稅導致的成本波動可能會影響合約談判、供應商多元化以及近岸外包和區域製造方案的優先排序。

透過對產品類型、醫療設備模式、臨床應用和最終用戶進行細分，可以明確使用模式和採購行為。

細分市場分析揭示了不同產品系列、治療方式、臨床適應症和醫療機構的不同趨勢，有助於制定有針對性的市場進入策略。產品層面的差異化至關重要，因為中心靜脈導管和周邊靜脈導管在臨床應用場景、置入流程和維護需求方面存在差異，而植入式輸液港則適用於長期治療方案，並需要進行手術調整。輸液幫浦提供了多種選擇：彈性體系統簡化了門診給藥，注射式幫浦可實現精確的大劑量投藥，而容積幫浦則支援複雜的可程式設計給藥方案。無針連接器進一步有助於預防感染和最佳化管路維護通訊協定，進而影響設備組合和臨床偏好。

區域比較分析涵蓋美洲、歐洲、中東、非洲和亞太地區的採用促進因素、法規、供應彈性和取得途徑。

區域趨勢影響化療設備的普及曲線和營運重點，美洲、歐洲、中東、非洲和亞太地區面臨不同的促進因素和限制因素。在美洲，醫療系統和保險公司優先考慮成本控制和治療效果評估，因此需要能夠展現營運效率和可衡量的安全效益的設備。同時，歐洲、中東和非洲地區則以多元化的管理體制和報銷環境為特徵，這些環境在評估​​臨床效益和成本效益證據的同時，也強調跨司法管轄區安全標準的協調統一。

從企業層面深入了解創新通路、夥伴關係策略、監管里程碑和市場進入策略，從而確定競爭定位。

化療醫療設備產業的企業層面發展趨勢體現了一種務實的策略，即投資創新、建立夥伴關係和擴大營運規模，所有這些都旨在滿足臨床醫生和支付方的期望。主要企業正優先開發完善的臨床證據包和上市後調查計畫，以支持監管申報和與支付方的諮詢。他們也積極尋求與醫療系統、契約製造和技術合作夥伴建立策略夥伴關係，以縮短產品部署時間，並提升生產能力和供應鏈透明度。

為行業領導者提供可操作的建議，以加速創新應用、最佳化供應鏈、與臨床醫生合作並改善患者療效。

行業領導者應推動一系列平衡舉措，協調臨床價值、營運韌性和商業性透明度，以實現永續的市場成長。首先，應優先創建並傳播嚴謹的臨床證據和真實世界結果，以直接解決臨床醫生對安全性、劑量準確性和護理連續性的擔憂。其次，應投資於供應鏈多元化和區域製造夥伴關係，以提高對區域採購需求的應對力，同時降低關稅和物流風險。第三，應設計支援醫院和居家照護的設備生態系統和服務，並透過培訓、遠端監測和技術支援來降低部署障礙。

高度透明的調查方法，詳細說明了資料來源、一手和二手調查的整合、專家檢驗、資料檢驗和品質檢查。

本研究採用結構化且透明的研究方法，整合了質性訪談、有針對性的二手研究以及系統性的資料三角驗證，以確保獲得可靠的洞見和令人信服的調查方法。一手研究包括與臨床醫生、採購經理、設備工程師和相關人員進行深入訪談，以揭示實際操作、預期證據和實施限制。二手研究整合了監管指南、臨床實踐文獻和公共趨勢，為相關人員訪談中湧現的主題提供背景資訊和佐證。

一份總結性綜合報告，重點闡述了策略意義、臨床意義以及透過醫療設備創新改善患者照護的協作行動的必要性。

本執行摘要強調了一項明確的要求：化療醫療設備的策略必須兼顧臨床療效、營運韌性和以病人為中心的服務模式。其關鍵意義包括：設計能夠同時支援住院和門診病人工作流程的醫療設備至關重要；需要強力的臨床證據來說服監管機構和支付者；以及價值鏈透明度對於降低政策和物流風險的策略價值。這些主題共同表明了營運方面的優先事項，例如臨床醫生培訓、庫存管理以及能夠實現規模化和可靠性的夥伴關係模式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：化療設備市場：依產品類型分類

  • 導管
    • 中央靜脈導管
    • 周邊導管
  • 嵌入式連接埠
  • 點滴幫浦
    • 彈性體泵
    • 注射式幫浦
    • 容積式泵
  • 無針頭連接器

第9章：化療設備市場：依治療方式分類

  • 攜帶式設備
  • 固定設備

第10章：化療設備市場：依應用領域分類

  • 乳癌
  • 結腸癌
  • 白血病
  • 肺癌
  • 攝護腺癌

第11章：化療設備市場：依最終用戶分類

  • 門診手術中心
  • 居家醫療設施
  • 醫院和診所

第12章：化療設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：化療設備市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：化療設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國化療設備市場

第16章：中國化療設備市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ACE Medical Co., Ltd.
  • AngioDynamics, Inc.
  • Arcomed AG
  • Avanos Medical, Inc.
  • B. Braun SE
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Cardinal Health, Inc.
  • CODAN Medizinische Gerate GmbH
  • Districlass Medical SA
  • ICU Medical, Inc.
  • InfuSystems, Inc.
  • Intera Oncology Inc. by Boston Scientific Corporation
  • Leventon SAU by Werfen, SA
  • Medtronic plc
  • Micrel Medical Devices SA
  • Mindray Medical International Limited
  • Nipro Corporation
  • Poly Medicure Limited
  • RenovoRx, Inc.
  • Shenzhen MedRena Biotech Co., Ltd.
  • Teleflex Incorporated
  • Terumo Corporation
  • ThermaSolutions Inc.
Product Code: MRR-3204321AF6C6

The Chemotherapy Device Market was valued at USD 3.84 billion in 2025 and is projected to grow to USD 4.11 billion in 2026, with a CAGR of 7.51%, reaching USD 6.38 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.84 billion
Estimated Year [2026] USD 4.11 billion
Forecast Year [2032] USD 6.38 billion
CAGR (%) 7.51%

Comprehensive introduction to the chemotherapy device landscape highlighting clinical imperatives, technological evolution, regulatory dynamics and priorities

This executive summary opens with a succinct orientation to the chemotherapy device domain, clarifying the clinical context, key technology categories, and stakeholder priorities shaping adoption. Chemotherapy delivery continues to evolve as clinicians and health systems pursue safer, more precise and patient-centered modalities that reduce infusion errors, minimize hospital stays, and improve therapy continuity. In parallel, device innovators emphasize interoperability, usability, and evidence generation to meet the heightened expectations of regulators, payers, and care teams.

As a result, strategic decision-makers must balance clinical needs, operational imperatives, and regulatory considerations when evaluating device portfolios or forming partnerships. This introduction frames the subsequent analysis by highlighting how device design choices influence clinical workflows, how modality selection affects care settings, and how end-user capabilities determine implementation timelines. It sets the scene for deeper examination of technological shifts, policy influences, segmentation behaviors, regional nuances, and actionable recommendations for stakeholders aiming to strengthen competitive positioning and patient outcomes.

Exploration of transformative shifts redefining chemotherapy device innovation, clinical workflows, regulatory expectations and patient-centered delivery models

The chemotherapy device landscape is experiencing a sequence of transformative shifts driven by advances in device miniaturization, connectivity, and human factors engineering. New device form factors and integrated safety features are redefining clinical workflows, enabling care to move closer to the patient through home-based and outpatient pathways. At the same time, digital tools and data capture capabilities foster tighter clinician oversight, remote monitoring, and post-market evidence collection, which together accelerate iterative product improvements and clinical acceptance.

Concurrently, regulatory expectations have evolved to emphasize real-world evidence and demonstrable risk mitigation, prompting manufacturers to invest earlier in clinical validation and user-centered design. Reimbursement strategies and procurement practices are likewise adapting, with payers and providers seeking value propositions that reduce total cost of care and enable predictable therapy delivery. Taken together, these shifts create both opportunity and complexity: stakeholders must navigate faster innovation cycles, tighter evidence requirements, and the need to demonstrate seamless integration into existing care pathways while preserving safety and reliability.

Evaluation of the cumulative effects of recent United States tariff policy on chemotherapy device supply chains, procurement approaches and clinical access

Recent tariff actions in the United States have introduced a cumulative set of pressures on the chemotherapy device ecosystem that manifest across manufacturing, sourcing, and procurement channels. Manufacturers with global supply footprints face elevated input costs and potential supply reallocation decisions, while procurement teams and hospital purchasing functions must reassess sourcing strategies to preserve budgetary predictability. In addition, tariff-driven cost dynamics can affect contract negotiations, supplier diversification initiatives, and the prioritization of nearshoring or regionalized manufacturing options.

Beyond direct cost implications, tariffs influence investment planning and the cadence of new product introductions. Manufacturers and contract manufacturers may accelerate supply chain resiliency programs and supplier qualification efforts to minimize exposure. Clinicians and health systems may experience downstream impacts through shifts in device availability, lead times, or procurement complexity, prompting programs to enhance inventory management and clinical training on alternate device platforms. Overall, tariff policy amplifies the importance of supply chain transparency, flexible sourcing strategies, and close alignment between commercial, regulatory, and operations teams to maintain clinical continuity.

Segmentation insights across product types, device modalities, clinical applications and end users that clarify utilization patterns and procurement behavior

Segmentation analysis reveals differentiated dynamics across product families, modalities, clinical indications and care settings that inform targeted go-to-market strategies. Product-level distinctions matter as central venous and peripheral catheter choices have distinct clinical use cases, implantation workflows and maintenance needs, while implantable ports serve longer-term therapy plans and require surgical coordination. Infusion pumps exhibit considerable diversity: elastomeric systems offer simplicity for ambulatory administration, syringe pumps enable precise bolus control, and volumetric pumps support complex programmable regimens. Needleless connectors further contribute to infection prevention and line maintenance protocols that shape device bundles and clinical preferences.

Modality segmentation separates portable devices that enable home and ambulatory infusion from stationary platforms designed for hospital-based administration, each presenting unique training, monitoring, and service requirements. Clinical application segmentation highlights that device selection and protocol design vary across breast, colorectal, leukemia, lung, and prostate oncology pathways due to differences in regimen complexity, infusion frequency, and patient comorbidity profiles. End-user contexts, including ambulatory surgical centers, homecare settings, and hospitals and clinics, drive procurement cycles, staff competencies, and logistical considerations, which necessitate tailored value propositions and service models for successful adoption.

Comparative regional insights for Americas, Europe Middle East & Africa, and Asia-Pacific covering adoption drivers, regulation, supply resilience and access

Regional dynamics shape both the adoption curve and operational priorities for chemotherapy devices, with distinct drivers and constraints across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, health systems and payers emphasize cost containment and outcome measurement, prompting device offerings that demonstrate operational efficiencies and measurable safety benefits. Meanwhile, Europe Middle East & Africa features a mosaic of regulatory regimes and reimbursement environments that reward evidence of clinical benefit and cost-effectiveness while emphasizing harmonized safety standards across jurisdictions.

Asia-Pacific presents rapid adoption pockets driven by growing oncology caseloads, investment in outpatient and homecare infrastructure, and an increasing focus on localized manufacturing to improve supply continuity. Across all regions, supply resilience, regulatory alignment, and clinician education emerge as common priorities, yet the relative weight of each factor varies by market. Consequently, manufacturers and providers must adapt deployment models, training programs, and commercial approaches to align with regional reimbursement frameworks, local clinician practice patterns, and infrastructure maturity to ensure consistent patient access and sustained utilization.

Company-level insights on innovation pipelines, partnership strategies, regulatory milestones and go-to-market approaches that define competitive positioning

Company-level behaviors in the chemotherapy device sector reflect a pragmatic mix of innovation investment, partnership formation, and operational scaling aimed at meeting clinician and payer expectations. Leading firms prioritize building robust clinical evidence packages and post-market surveillance programs to support regulatory submissions and payer conversations. They also pursue strategic collaborations with health systems, contract manufacturers, and technology partners to accelerate time-to-adoption and to fortify manufacturing capacity and supply chain visibility.

Commercial tactics include differentiated service offerings such as training programs, clinical support, and data analytics services that reinforce product value beyond hardware. Additionally, companies are increasingly attentive to human factors and usability as sources of competitive advantage, investing in iterative design and clinician co-creation. From an operational perspective, resilience initiatives-such as multi-sourcing key components, qualifying regional manufacturing partners, and enhancing logistics planning-are central to maintaining product availability and sustaining trust with health system customers.

Practical recommendations for industry leaders to accelerate innovation adoption, optimize supply chains, engage clinicians and improve patient outcomes

Industry leaders should pursue a balanced set of initiatives that align clinical value, operational resilience, and commercial clarity to achieve sustained market traction. First, prioritize generation and communication of rigorous clinical evidence and real-world outcomes that directly address clinician concerns about safety, dosing accuracy, and therapy continuity. Second, invest in supply chain diversification and regional manufacturing partnerships to mitigate tariff and logistics risks, while improving responsiveness to local procurement requirements. Third, design device ecosystems and services that support both hospital and home-based care, ensuring that training, remote monitoring, and technical support reduce implementation friction.

In addition, companies should tailor reimbursement and pricing strategies to reflect total cost of care impacts, engaging early with payers and providers to demonstrate economic as well as clinical benefits. Strengthening clinician partnerships through co-development and demonstration pilots will accelerate adoption, while integrating user-centered design principles will minimize training burdens and enhance safety. Finally, establish clear cross-functional governance that links clinical evidence, regulatory strategy, and commercial execution to enable rapid, coordinated responses to market and policy shifts.

Transparent research methodology detailing data sources, integration of primary and secondary research, expert validation, data triangulation and quality checks

The research employed a structured, transparent methodology that integrates primary qualitative interviews, targeted secondary research, and systematic data triangulation to ensure robust findings and defensible insights. Primary research included in-depth conversations with clinicians, procurement leaders, device engineers, and policy stakeholders to surface operational realities, evidence expectations, and adoption constraints. Secondary research synthesized regulatory guidance, clinical practice literature, and public policy developments to provide context and to corroborate themes emerging from stakeholder interviews.

To enhance reliability, the study applied data triangulation by cross-referencing interview insights with published clinical guidelines, regulatory documentation, and supply chain evidence. Expert validation workshops were used to stress-test assumptions, refine segmentation frameworks, and prioritize recommendations. Quality checks included audit trails of primary sources, consistency reviews across analysts, and version-controlled synthesis steps to maintain methodological rigor and transparency throughout the analysis.

Conclusive synthesis highlighting strategic takeaways, clinical implications and the need for collective action to improve patient care through device innovation

This executive synthesis underscores a clear imperative: chemotherapy device strategies must align clinical effectiveness with operational resilience and patient-centered delivery models. Key takeaways include the importance of device design that supports both inpatient and outpatient workflows, the necessity of robust clinical evidence to satisfy regulators and payers, and the strategic value of supply chain transparency to mitigate policy and logistics risks. These themes collectively inform operational priorities such as clinician training, inventory management, and partnership models that enable scale and reliability.

Moving forward, stakeholders should pursue coordinated initiatives that integrate product development, regulatory strategy, and commercial planning to deliver demonstrable improvements in therapy safety and continuity. By emphasizing iterative evidence generation, flexible manufacturing, and clinician engagement, organizations can bridge the gap between technological capability and real-world impact. Ultimately, success in this space will depend on collaborative approaches that align incentives across manufacturers, providers, and payers to strengthen patient outcomes and operational sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chemotherapy Device Market, by Product Type

  • 8.1. Catheters
    • 8.1.1. Central Venous Catheters
    • 8.1.2. Peripheral Catheters
  • 8.2. Implantable Ports
  • 8.3. Infusion Pumps
    • 8.3.1. Elastomeric Pumps
    • 8.3.2. Syringe Pumps
    • 8.3.3. Volumetric Pumps
  • 8.4. Needleless Connectors

9. Chemotherapy Device Market, by Modality

  • 9.1. Portable Devices
  • 9.2. Stationary Devices

10. Chemotherapy Device Market, by Application

  • 10.1. Breast Cancer
  • 10.2. Colorectal Cancer
  • 10.3. Leukemia
  • 10.4. Lung Cancer
  • 10.5. Prostate Cancer

11. Chemotherapy Device Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Homecare Settings
  • 11.3. Hospitals & Clinics

12. Chemotherapy Device Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Chemotherapy Device Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Chemotherapy Device Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Chemotherapy Device Market

16. China Chemotherapy Device Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. ACE Medical Co., Ltd.
  • 17.6. AngioDynamics, Inc.
  • 17.7. Arcomed AG
  • 17.8. Avanos Medical, Inc.
  • 17.9. B. Braun SE
  • 17.10. Baxter International Inc.
  • 17.11. Becton, Dickinson and Company
  • 17.12. Cardinal Health, Inc.
  • 17.13. CODAN Medizinische Gerate GmbH
  • 17.14. Districlass Medical SA
  • 17.15. ICU Medical, Inc.
  • 17.16. InfuSystems, Inc.
  • 17.17. Intera Oncology Inc. by Boston Scientific Corporation
  • 17.18. Leventon S.A.U. by Werfen, S.A.
  • 17.19. Medtronic plc
  • 17.20. Micrel Medical Devices SA
  • 17.21. Mindray Medical International Limited
  • 17.22. Nipro Corporation
  • 17.23. Poly Medicure Limited
  • 17.24. RenovoRx, Inc.
  • 17.25. Shenzhen MedRena Biotech Co., Ltd.
  • 17.26. Teleflex Incorporated
  • 17.27. Terumo Corporation
  • 17.28. ThermaSolutions Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHEMOTHERAPY DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHEMOTHERAPY DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CHEMOTHERAPY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CHEMOTHERAPY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY CENTRAL VENOUS CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY CENTRAL VENOUS CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY CENTRAL VENOUS CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY PERIPHERAL CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY PERIPHERAL CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY PERIPHERAL CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY IMPLANTABLE PORTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY IMPLANTABLE PORTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY IMPLANTABLE PORTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY ELASTOMERIC PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY ELASTOMERIC PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY ELASTOMERIC PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY SYRINGE PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY SYRINGE PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY SYRINGE PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY VOLUMETRIC PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY VOLUMETRIC PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY VOLUMETRIC PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY NEEDLELESS CONNECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY NEEDLELESS CONNECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY NEEDLELESS CONNECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY PORTABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY PORTABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY PORTABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY STATIONARY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY STATIONARY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY STATIONARY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS CHEMOTHERAPY DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS CHEMOTHERAPY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS CHEMOTHERAPY DEVICE MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS CHEMOTHERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS CHEMOTHERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA CHEMOTHERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA CHEMOTHERAPY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA CHEMOTHERAPY DEVICE MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA CHEMOTHERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA CHEMOTHERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA CHEMOTHERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA CHEMOTHERAPY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA CHEMOTHERAPY DEVICE MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA CHEMOTHERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA CHEMOTHERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY DEVICE MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE CHEMOTHERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE CHEMOTHERAPY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE CHEMOTHERAPY DEVICE MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE CHEMOTHERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE CHEMOTHERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST CHEMOTHERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST CHEMOTHERAPY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST CHEMOTHERAPY DEVICE MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST CHEMOTHERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST CHEMOTHERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA CHEMOTHERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA CHEMOTHERAPY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA CHEMOTHERAPY DEVICE MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA CHEMOTHERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA CHEMOTHERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC CHEMOTHERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC CHEMOTHERAPY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CHEMOTHERAPY DEVICE MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CHEMOTHERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CHEMOTHERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN CHEMOTHERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN CHEMOTHERAPY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN CHEMOTHERAPY DEVICE MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN CHEMOTHERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN CHEMOTHERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. GCC CHEMOTHERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC CHEMOTHERAPY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 133. GCC CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 134. GCC CHEMOTHERAPY DEVICE MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 135. GCC CHEMOTHERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. GCC CHEMOTHERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION CHEMOTHERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION CHEMOTHERAPY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION CHEMOTHERAPY DEVICE MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION CHEMOTHERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION CHEMOTHERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS CHEMOTHERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS CHEMOTHERAPY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS CHEMOTHERAPY DEVICE MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS CHEMOTHERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS CHEMOTHERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. G7 CHEMOTHERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 CHEMOTHERAPY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 154. G7 CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 155. G7 CHEMOTHERAPY DEVICE MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 156. G7 CHEMOTHERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. G7 CHEMOTHERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NATO CHEMOTHERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO CHEMOTHERAPY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 161. NATO CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 162. NATO CHEMOTHERAPY DEVICE MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 163. NATO CHEMOTHERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NATO CHEMOTHERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CHEMOTHERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES CHEMOTHERAPY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES CHEMOTHERAPY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES CHEMOTHERAPY DEVICE MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES CHEMOTHERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES CHEMOTHERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA CHEMOTHERAPY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA CHEMOTHERAPY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA CHEMOTHERAPY DEVICE MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA CHEMOTHERAPY DEVICE MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA CHEMOTHERAPY DEVICE MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA CHEMOTHERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA CHEMOTHERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)